RIGL vs. CLDX, MNKD, MYGN, NVAX, INVA, OPK, EBS, CDXS, XOMA, and IRWD
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Celldex Therapeutics (CLDX), MannKind (MNKD), Myriad Genetics (MYGN), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Emergent BioSolutions (EBS), Codexis (CDXS), XOMA (XOMA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.
Rigel Pharmaceuticals vs.
Celldex Therapeutics (NASDAQ:CLDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Celldex Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Celldex Therapeutics received 158 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. Likewise, 75.27% of users gave Celldex Therapeutics an outperform vote while only 68.90% of users gave Rigel Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics currently has a consensus price target of $60.22, indicating a potential upside of 168.13%. Rigel Pharmaceuticals has a consensus price target of $36.20, indicating a potential upside of 80.19%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Rigel Pharmaceuticals.
In the previous week, Celldex Therapeutics had 6 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 10 mentions for Celldex Therapeutics and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.96 beat Celldex Therapeutics' score of 0.67 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Celldex Therapeutics' net margin of -1,544.32%. Rigel Pharmaceuticals' return on equity of -14.80% beat Celldex Therapeutics' return on equity.
Summary
Rigel Pharmaceuticals beats Celldex Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RIGL) was last updated on 2/21/2025 by MarketBeat.com Staff
